Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelica Calleri

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Leukemia & Lymphoma|June 29, 2010
Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patientsPaola Bertazzoni, Cristina Rabascio, Federica Gigli, et al.
Cancers|September 23, 2022
Addressing the Role of Angiogenesis in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus: A Biological Prospective Analysis of Soluble Biomarkers and Clinical OutcomesChiara Alessandra Cella, Francesca Spada, Alfredo Berruti, et al.
Cancer Research|August 7, 2013
Complementary populations of human adipose CD34+ progenitor cells promote growth, angiogenesis, and metastasis of breast cancerStefania Orecchioni, Giuliana Gregato, Ines Martin-Padura, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 28, 2019
Correction: Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specifiedMaria Antonella Laginestra, Luciano Cascione, Giovanna Motta, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 28, 2019
Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specifiedMaria Antonella Laginestra, Luciano Cascione, Giovanna Motta, et al.
Ejhaem|February 10, 2025
Immune Signatures Identify Patient Subsets Deriving Long-Term Benefit From First-Line Rituximab in Follicular LymphomaGinevra Lolli, Alessandro Davini, Valentina Tabanelli, et al.
Leukemia|July 25, 2021
Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphomaAlessandra Rossi, Stefania Orecchioni, Paolo Falvo, et al.
Blood Advances|June 29, 2022
The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockadeValentina Tabanelli, Federica Melle, Giovanna Motta, et al.
The Lancet. Oncology|September 13, 2024
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trialAlessandra Tedeschi, Anna Maria Frustaci, Adalgisa Condoluci, et al.
Haematologica|August 21, 2020
A three-gene signature based on <i>MYC</i>, <i>BCL-2</i> and <i>NFKBIA</i> improves risk stratification in diffuse large B-cell lymphomaEnrico Derenzini, Saveria Mazzara, Federica Melle, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Leukemia & Lymphoma|June 29, 2010
Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patientsPaola Bertazzoni, Cristina Rabascio, Federica Gigli, et al.
Cancers|September 23, 2022
Addressing the Role of Angiogenesis in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus: A Biological Prospective Analysis of Soluble Biomarkers and Clinical OutcomesChiara Alessandra Cella, Francesca Spada, Alfredo Berruti, et al.
Cancer Research|August 7, 2013
Complementary populations of human adipose CD34+ progenitor cells promote growth, angiogenesis, and metastasis of breast cancerStefania Orecchioni, Giuliana Gregato, Ines Martin-Padura, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 28, 2019
Correction: Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specifiedMaria Antonella Laginestra, Luciano Cascione, Giovanna Motta, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 28, 2019
Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specifiedMaria Antonella Laginestra, Luciano Cascione, Giovanna Motta, et al.
Ejhaem|February 10, 2025
Immune Signatures Identify Patient Subsets Deriving Long-Term Benefit From First-Line Rituximab in Follicular LymphomaGinevra Lolli, Alessandro Davini, Valentina Tabanelli, et al.
Leukemia|July 25, 2021
Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphomaAlessandra Rossi, Stefania Orecchioni, Paolo Falvo, et al.
Blood Advances|June 29, 2022
The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockadeValentina Tabanelli, Federica Melle, Giovanna Motta, et al.
The Lancet. Oncology|September 13, 2024
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trialAlessandra Tedeschi, Anna Maria Frustaci, Adalgisa Condoluci, et al.
Haematologica|August 21, 2020
A three-gene signature based on <i>MYC</i>, <i>BCL-2</i> and <i>NFKBIA</i> improves risk stratification in diffuse large B-cell lymphomaEnrico Derenzini, Saveria Mazzara, Federica Melle, et al.
Pageof 5